Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 21, 2026 07:00 ET | Source: Amphista Therapeutics

Amphista Therapeutics presents the discovery, characterisation and chemical structure of AMX-883, an orally bioavailable, highly potent and selective DCAF16 degrader of BRD9 at AACR 2026

First public disclosure of the chemical structure of AMX-883, an orally bioavailable, highly potent and selective DCAF16-dependent Targeted Glue™ degrader of BRD9 AMX-883 is the Company’s lead asset...
April 21, 2026 02:00 ET | Source: Amphista Therapeutics

Amphista Therapeutics presents the discovery, characterisation and chemical structure of AMX-883, an orally bioavailable, highly potent and selective DCAF16 degrader of BRD9 at AACR 2026

First public disclosure of the chemical structure of AMX-883, an orally bioavailable, highly potent and selective DCAF16-dependent Targeted Glue™ degrader of BRD9 AMX-883 is the Company’s lead asset...
May 23, 2024 07:00 ET | Source: Amphista Therapeutics

Amphista Therapeutics unveils new differentiated mechanism of action for BRD9 degradation at 2024 Protein Degradation in Focus Symposium

PRESS RELEASE Amphista Therapeutics unveils new differentiated mechanism of action for BRD9 degradation at 2024 Protein Degradation in Focus Symposium First presentation of a novel mechanism of...